rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    ELVN
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Enliven Therapeutics Stock In Focus After Wider Loss And FDA Trial Alignment
      Nov 7Yahoo FinanceELVN
      Enliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business Update
      Nov 5Yahoo FinanceELVN
      Enliven Therapeutics CFO Hohl sells $231,545 in shares
      Oct 22Investing.comELVN
      Enliven Therapeutics CMO Collins sells $192,342 in ELVN stock
      Oct 21Investing.comELVN
      H.C. Wainwright raises Enliven Therapeutics price target to $73
      Oct 19Investing.comELVN
      Enliven Therapeutics appoints Kristine Ball to board
      Oct 14Investing.comELVN
      Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year
      Oct 14Yahoo FinanceELVN
      Enliven Therapeutics director Scott Garland sells $606k in stock
      Oct 12Investing.comELVN
      Why Enliven Therapeutics' (ELVN) ENABLE-2 Trial Design Raises New Questions About Its CML Strategy
      Oct 10Yahoo FinanceELVN
      Guggenheim reiterates Enliven Therapeutics stock rating on FDA alignment
      Oct 8Investing.comELVN
      Enliven Therapeutics Reaches Realignment With FDA on Final Design of Relcobatinib's Phase 3 Trial
      Oct 7Yahoo FinanceELVN
      This Enliven Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Frida

      Analysts initiated coverage: VYLR Outperform/$85, LBRX Buy/$68, ELVN Overweight/$70, SAIL Sector Weight, and AVLN Outperform/$60.

      Oct 2BenzingaELVN
      Morgan Stanley initiates Enliven Therapeutics stock at overweight
      Oct 2Investing.comELVN
      Morgan Stanley Initiates Enliven Therapeutics at Overweight
      Oct 2Yahoo FinanceELVN
      Enliven Therapeutics stock initiated at Overweight by JPMorgan
      Oct 1Investing.comELVNJPM
      JPMorgan Initiates Enliven Therapeutics at Overweight With $75 Price Target
      Oct 1Yahoo FinanceELVN
      Enliven Therapeutics CMO Helen Collins sells $251k in shares
      Sep 22Investing.comELVN
      Enliven Therapeutics CFO Benjamin Hohl sells $303,003 in stock
      Sep 22Investing.comELVN
      Enliven Therapeutics Insider Sold Shares Worth $303,003, According to a Recent SEC Filing

      Benjamin Hohl, CFO, on September 17, 2026, sold 6,018 shares in Enliven Therapeutics (ELVN) for $303

      Sep 21Yahoo FinanceELVN
      Enliven Therapeutics Insider Sold Shares Worth $251,754, According to a Recent SEC Filing

      Helen Louise Collins, Chief Medical Officer, on September 17, 2026, sold 5,000 shares in Enliven The

      Sep 21Yahoo FinanceELVN
      Enliven Therapeutics at Morgan Stanley conference: cash, trials and CML
      Sep 16Investing.comELVNMS
      Enliven Therapeutics: A Clean Active-Site TKI Could Redefine CML Sequencing (NASDAQ:ELVN)
      Sep 3Seeking AlphaELVN
      Enliven Therapeutics to Present at Upcoming Investor Conferences
      Sep 3Yahoo FinanceELVN
      Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
      Aug 31MorningstarELVN
      Analysts Are Bullish on Top Healthcare Stocks: Enliven Therapeutics (ELVN), Argenx Se (ARGX)

      Detailed price information for Aquestive Therapeutics Inc (AQST-Q) from The Globe and Mail including charting and trades.

      Aug 25The Globe and MailARGXELVN

      This is the newest page. Registered accounts read further back.